Latest Biotech News

An analysis found that despite sweeping staff departures and leadership churn at the FDA in 2025, reviewers met the majority of user‑fee commitments for new drug reviews and approvals. The report...

Guardant Health said Tricare will cover its Shield blood‑based colorectal cancer screening test, making Shield available with no copay to active‑duty service members and their families aged 45 and...

Eli Lilly agreed to acquire San Diego‑based Ventyx Biosciences for roughly $1.2 billion in cash, buying a mid‑stage oral NLRP3 inhibitor program the buyer calls strategically complementary to its...

Aktis Oncology priced an initial public offering that raised about $318 million, marking the first US biotech IPO of 2026 and signaling renewed public‑market appetite for radiopharmaceuticals. The...

Mediar Therapeutics closed an oversubscribed $76 million Series B co‑led by ICG Life Sciences and Amplitude Ventures to accelerate clinical development of multiple anti‑fibrotic antibodies. The...

Parabilis Medicines raised $305 million in an oversubscribed Series F to advance its Helicon‑derived corkscrew peptide platform and lead candidate zolucatetide toward later‑stage studies. The...

EpiBiologics closed a $107 million Series B led by GV and Johnson & Johnson’s venture arm to advance its EpiTAC platform and lead bispecific degrader EPI‑326 into first‑in‑human studies. The Bay...

Immuneering reported updated phase IIa data showing a 64% overall survival rate at 12 months for atebimetinib combined with modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer,...

OpenAI announced ChatGPT for Healthcare, a product intended to integrate the company’s large language models with hospital systems, followed by the consumer‑facing ChatGPT Health feature that...

GSK and Ionis reported that bepirovirsen, an antisense oligonucleotide, met primary endpoints in two pivotal Phase 3 trials and achieved functional cure rates in chronic hepatitis B patients. The...

Alveus Therapeutics emerged with about $160 million in Series A capital to advance a Phase‑2‑ready obesity candidate that targets the same dual pathways as Amgen’s MariTide, plus an...

Storm Therapeutics announced a collaboration with Alida Biosciences to apply AlidaBio’s EpiPlex/EpiScout epitranscriptome platforms to clinical samples from patients treated with Storm’s METTL3...

Aktis Oncology completed a $318 million initial public offering and will trade on Nasdaq under ticker AKTS. The Boston-based radiopharmaceutical developer priced 17.65 million shares at $18 each...

Eli Lilly agreed to acquire San Diego–based Ventyx Biosciences for about $1.2 billion in an all‑cash deal at $14 per share, a roughly 62% premium to the recent trading average. Ventyx’s lead...

Parabilis Medicines closed a $305 million Series F round led by RA Capital, Fidelity and Janus Henderson to advance its Helicon peptide platform and lead candidate zolucatetide toward later‑stage...

Immuneering released updated Phase IIa data for atebimetinib combined with modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer, reporting a 64% overall survival rate at 12 months...

GSK and Ionis reported that their antisense therapy bepirovirsen met primary endpoints across two pivotal Phase III studies, achieving statistically meaningful functional cure rates in chronic...

Storm Therapeutics entered a strategic collaboration with Alida Biosciences to quantify transcript‑specific N6‑methyladenosine (m6A) RNA modifications in clinical samples from patients treated...

EpiBiologics closed a $107 million Series B, backed by investors including GV and Johnson & Johnson’s venture arm, to advance its surface‑targeted protein degradation platform (EpiTACs) and lead...

OpenAI announced ChatGPT for Healthcare, a tailored offering that brings the ChatGPT conversational AI into hospital and health‑system workflows. The launch follows consumer health features and is...